Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ADUS vs PACS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADUS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–4 Matrix Metrics)

ADUS Overall Winner 6-Pillar Tally: ADUS 4 – 2 PACS Matrix Metrics: ADUS 5 – 4 PACS

As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over PACS Group, Inc. (PACS) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas PACS carries 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADUS vs PACS
ADUS NASDAQ Head-to-Head Winner
Addus HomeCare Corp.
Services-Home Health Care Services
$122.50
+1.18% 1D
Market Cap $2.3B
TTM Revenue $1.50B
Forward P/E 16.1x
Beta / 30D Vol -0.07β · 21% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 57.0 Fund 52.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 52
RSI-14: 51.6 · SMA20: $123.87 · SMA50: $118.74
PACS NYSE
PACS Group, Inc.
Services-Skilled Nursing Care Facilities
$43.67
+1.49% 1D
Market Cap $6.8B
TTM Revenue $5.71B
Forward P/E 15.3x
Beta / 30D Vol 0.78β · 51% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 35.0 Fund 48.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 39.2 · SMA20: $48.01 · SMA50: $45.43

6-Pillar Scorecard Institutional Category Breakdown (ADUS 4 – 2 PACS)

Columns: Metric · ADUS · PACS
1. Valuation Multiples ADUS
Forward P/E 16.1x 15.3x
Trailing P/E 20.1x 26.2x
PEG Ratio 1.05x 1.22x
EV / Revenue 1.5x 1.8x
2. Growth & Scale PACS
Revenue Growth (YoY) +7.0% +11.5%
Earnings Growth (YoY) +24.2% +15.6%
TTM Revenue (USD) $1.50B $5.71B
Market Cap $2.3B $6.8B
3. Profitability & Quality ADUS
Gross Margin 32.3% 17.8%
Operating Margin 10.4% 7.4%
Net Profit Margin 7.4% 4.9%
Return on Equity (ROE) 10.0% 26.5%
4. Balance Sheet & Cash Flow ADUS
Cash Generation (TTM) $173M EBITDA $8.2M
Cash Flow Margin 11.5% EBITDA Mgn 0.1%
Net Cash / Leverage $64.64 Book/Sh · 10.0% ROE $3.29B Net Debt (2.81x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PACS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 21.9% (16th %ile) 46.1% (11th %ile)
Put/Call OI Skew N/A 0.52x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ADUS
OpEx & R&D Intensity 21.9% of Rev ($329M) 10.4% of Rev ($593M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADUS (5) vs PACS (4)
Institutional Metric ADUS PACS Criterion Row Edge
Market Capitalization
Scale
$2.3B $6.8B Larger Scale PACS
Trailing P/E Ratio
Valuation
20.1x 26.2x Lower Multiple ADUS
Forward P/E Ratio
Valuation
16.1x 15.3x Lower Multiple PACS
Revenue Growth (YoY)
Growth
+7.0% +11.5% Higher Growth PACS
Operating Margin (TTM)
Profitability
10.4% 7.4% Higher Margin ADUS
Net Profit Margin
Profitability
7.4% 4.9% Higher Margin ADUS
Return on Equity (ROE)
Capital Efficiency
10.0% 26.5% Higher ROE PACS
52-Week Range Position
Momentum
79% ($88–$132) 79% ($14–$52) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
-0.07β · 21% Vol 0.78β · 51% Vol Lower Realized Risk ADUS
Unified Institutional Score
Composite Signal
59.0 / 100 (HOLD) 46.8 / 100 (HOLD) Higher Composite ADUS
Trailing 12M Revenue (USD)
Operating Scale
$1.50B $5.71B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
32.3% 17.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.05x PEG · 1.5x EV/Rev 1.22x PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$173M EBITDA ($64.64 Book/Sh · 10.0% ROE) $8.2M ($3.29B Net Debt (2.81x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADUS +7.92 pp
ADUS: -0.14% · PACS: -8.06%
3M Horizon ADUS +2.7 pp
ADUS: +1.39% · PACS: -1.31%
6M Horizon ADUS +16.54 pp
ADUS: +32.22% · PACS: +15.68%
1Y Horizon PACS +147.09 pp
ADUS: +12.39% · PACS: +159.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADUS vs PACS. Trailing 12-month operating profitability (ADUS 10.4% vs PACS 7.4%) and valuation multiples (ADUS 16.1x vs PACS 15.3x Forward P/E) are benchmarked directly in Pillar 4 below.

ADUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.50B
Gross Margin32.3%
Op. Margin10.4%
ROE / Fwd P/E10.0% · 16.1x
PACS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.71B
Gross Margin17.8%
Op. Margin7.4%
ROE / Fwd P/E26.5% · 15.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACS CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 46.1%
IV Percentile 11th %ile
Put/Call OI Skew 0.52x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PACS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $49.00 · IV 47.5%

PACS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($4,900)

Compare $4,900 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 47.5% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $50 / $55 Bull Call Spread

Buy 1x $50C · Sell 1x $55C · 32d

Net Entry $103 Debit
T+5d @ +5% Move +$65 (+63%)
Max Risk / Buffer $103 Capped
5d Edge & Liquidity 1.1x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $45 / $40 Bull Put Spread

Sell 1x $45P · Buy 1x $40P · 32d

Net Entry $104 Credit
Max Credit / Yield +$104 (+26.3% RoM)
Max Risk / Buffer -10.3% Cushion ($396 Mgn)
5d Edge & Liquidity 73% PoP · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $45P / $50-$55C Seagull

Sell 1x $45P · Buy 1x $50/$55C · 32d

Net Entry $47 Credit
T+5d @ +5% Move +$146 (+21.3% RoM)
Max Risk / Buffer -8.2% Put Cushion ($683 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADUS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.3B market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 21.9% of Rev ($329M)
90D Engineering Disclosures 0 Published
PACS Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $6.8B market capitalization and 7.4% operating margin.
OpEx & R&D Reinvestment 10.4% of Rev ($593M)
90D Engineering Disclosures 0 Published

Investor FAQ ADUS vs PACS Key Questions & Quantitative Answers

As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over PACS Group, Inc. (PACS) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas PACS carries 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin). Technically, ADUS sits in a Markup phase (RSI 51.6, UNCLASSIFIED options structure) and PACS sits in a Neutral phase (RSI 39.2, CONSOLIDATION options structure).

PACS leads the Growth & Scale pillar: ADUS posts +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin), compared with PACS at +11.5% YoY revenue growth and +15.6% YoY earnings growth on $5.71B TTM revenue (17.8% gross margin, 7.4% operating margin). On trailing 12-month operating scale, ADUS generates $1.50B in USD-normalized revenue versus $5.71B for PACS. In operating R&D and SG&A reinvestment, ADUS deploys 21.9% of Rev ($329M) (0 90-day corporate R&D disclosures) versus 10.4% of Rev ($593M) (0 disclosures) for PACS.

ADUS screens cheaper on headline valuation multiples. ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin), whereas PACS trades at 15.3x Forward P/E, 26.2x Trailing P/E, 1.22x PEG, and 1.8x EV/Revenue (0.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADUS (10.0% ROE) versus PACS (26.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk). By comparison, PACS carries 46.1% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.78β · 51% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.